Equities
Basic MaterialsChemicals
  • Price (USD)180.81
  • Today's Change3.32 / 1.87%
  • Shares traded224.97k
  • 1 Year change+10.83%
  • Beta0.9362
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

  • Revenue in USD (TTM)1.01bn
  • Net income in USD149.20m
  • Incorporated1967
  • Employees1.36k
  • Location
    Balchem Corp5 Paragon DriveMONTVALE 07645United StatesUSA
  • Phone+1 (845) 326-5600
  • Fax+1 (845) 326-5742
  • Websitehttps://balchem.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hawkins Inc1.06bn82.41m3.06bn1.04k37.135.8623.222.883.953.9550.9025.021.269.799.041,027,154.009.7910.8910.9712.9222.8620.357.757.431.4610.150.336519.526.0112.5211.9224.3510.858.70
Chemours Co5.87bn-333.00m3.08bn6.00k--10.32512.630.5238-2.22-2.2239.101.990.78123.257.15978,666.70-4.423.31-5.844.3917.3721.80-5.654.190.8831.720.932662.17-4.070.9098136.13---5.630.00
Quaker Chemical Corp1.86bn-8.99m3.11bn4.40k--2.2848.281.67-0.5086-0.5086105.9078.520.67154.654.34423,691.40-0.912.34-1.052.7035.9434.91-1.363.701.773.720.390240.97-5.8210.173.6329.8221.874.15
Perimeter Solutions Inc636.34m78.04m3.88bn319.0051.883.4926.046.100.50540.50544.267.510.24922.236.231,994,806.003.06-4.693.30-4.8458.2546.5612.26-24.791.720.87410.4159--74.1618.58-108.75--11.88--
Avient Corp3.25bn113.30m3.91bn9.20k34.691.6513.031.211.231.2335.3725.900.53645.726.84352,837.001.902.102.192.4932.2129.333.543.621.474.030.452277.893.112.51123.6117.528.335.97
Sensient Technologies Corp1.60bn139.11m3.95bn4.01k28.453.3519.752.483.273.2737.5027.780.75031.715.10397,380.206.546.277.407.1933.8832.708.728.201.797.780.376357.956.923.3133.488.738.652.21
Scotts Miracle-Gro Co3.35bn166.90m3.97bn2.10k24.47--16.431.182.791.4657.72-8.631.082.6116.451,595,571.005.38-1.037.28-1.3631.4727.724.98-0.98110.44033.531.25---3.93-3.75516.05-17.759.212.27
Cabot Corp3.61bn306.00m3.98bn4.06k13.382.537.881.105.695.6967.2030.160.9755.185.58887,549.209.3810.1912.6814.6425.4022.879.629.191.0912.830.394427.77-7.047.27-12.83--6.504.92
Newmarket Corp2.73bn417.13m5.57bn2.05k13.353.1310.292.0444.4244.42290.34189.230.82313.716.671,329,351.0012.6513.2714.3716.0231.4627.7915.3713.061.3313.700.331926.35-2.206.27-9.479.08-3.618.16
Balchem Corp1.01bn149.20m5.86bn1.36k39.654.5130.175.784.564.5630.9740.090.62225.188.04744,708.309.167.529.878.3035.8232.0714.7212.111.6717.670.107222.283.398.1818.3610.034.6510.84
Celanese Corp9.71bn-3.07bn6.44bn12.16k--1.63--0.6637-28.08-28.2688.6636.110.40413.208.07798,322.80-12.736.85-15.578.4621.3325.09-31.5013.971.042.060.745924.03-6.0310.30-176.89--3.293.13
Axalta Coating Systems Ltd5.12bn378.00m7.28bn12.60k19.623.1010.811.421.741.7423.5810.990.68934.504.49--5.114.136.305.1334.4332.267.416.011.504.250.5721---3.016.48-3.3225.4619.01--
Element Solutions Inc2.50bn239.40m7.83bn5.30k32.802.9519.993.130.98660.986610.3010.970.49285.035.12471,547.204.723.435.123.7142.0140.149.597.123.283.780.378537.525.306.00109.1425.1918.16--
Data as of Feb 13 2026. Currency figures normalised to Balchem Corp's reporting currency: US Dollar USD

Institutional shareholders

46.17%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 20254.42m13.65%
The Vanguard Group, Inc.as of 31 Dec 20253.60m11.13%
SSgA Funds Management, Inc.as of 31 Dec 20251.21m3.74%
Conestoga Capital Advisors LLCas of 31 Dec 20251.20m3.72%
Wasatch Advisors LPas of 31 Dec 20251.18m3.65%
Geode Capital Management LLCas of 31 Dec 20251.01m3.11%
Geneva Capital Management LLCas of 31 Dec 2025907.80k2.80%
Dimensional Fund Advisors LPas of 31 Dec 2025553.98k1.71%
JPMorgan Investment Management, Inc.as of 31 Dec 2025444.61k1.37%
Norges Bank Investment Managementas of 31 Dec 2025418.44k1.29%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.